MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Genocea Initiates a Phase 1/2a Study with its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2).
Guest UserAugust 15, 2012
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

Genocea Closes $30 Million in Series C Financing. The Bill & Melinda Gates Foundation and CVF join as new investors.

Guest UserOctober 10, 2012
Next

Genkyotex Raises CHF25 Million in Series C Round Extension.

Guest UserJuly 9, 2012

© 2010-2025 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact